Tobramycin (asTobramycin sulfate) 3 mg/ml
Dexamethasone phosphate (as
dexamethasone sodium phosphate) 1 mg/ml
Ampoule 3ml, 5ml, 10ml

Eye drops solution

Prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults and children aged 2 years and older.

• Adults:

  One drop instilled into the conjunctival sac(s) every 4 to 6 hours while the patient is awake. During the initial 24 to 48 hours, the dosage may be increased to one drop every two hours while the patient is awake. Dosing should continue for 14 days not to exceed a maximum of 24 days. Frequency should be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to discontinue therapy prematurely.

  Use in the Elderly:

  Clinical studies have indicated dosage modifications are not required for use in the elderly.

  Paediatric population:

  TOBRAMESON may be used in children 2 years of age and older at the same dose as in adults.

  The safety and efficacy in children younger than 2 years of age have not been established, and no data is available.

  Use in hepatic and renal impairment:

  TOBRAMESON has not been studied in these patient populations

  Shake the bottle well before use. To prevent contamination of the dropper tip and suspension, care should be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use. After cap is removed, if tamper evident snap collar is loose, remove before using product.

  Gently closing the eyelid (s) and nasolacrimal occlusion for at least 1 minute after instillation is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic side effects.

  In case of concomitant therapy with other topical ophthalmic medicinal products, an interval of 5 minutes should be allowed between successive applications.

  Eye ointments should be administered last.